TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04680117

Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: Blood collection with samples of 15ml max by subject (case or control) at J0, M6 and M12:~* subject less than 5 kg : 1.8 to 4.5 ml max~* subject 5 kg to 10 kg : 4.5 to 9 ml max~* subject 10 kg to 15 kg : 9 to 13.5 ml~* subject 15 kg to 20 kg : 13.5 to 15 ml max

Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: Blood collection with samples of 15ml max by subject (case or control) at J0, M6 and M12:~* subject less than 5 kg : 1.8 to 4.5 ml max~* subject 5 kg to 10 kg : 4.5 to 9 ml max~* subject 10 kg to 15 kg : 9 to 13.5 ml~* subject 15 kg to 20 kg : 13.5 to 15 ml max

Intervention type: OTHER
Group type: OTHER
Intervention: Saliva sample
Description: Saliva sample by subject at J0

Intervention type: OTHER
Group type: OTHER
Intervention: Saliva sample
Description: Saliva sample by subject at J0

Intervention type: OTHER
Group type: OTHER
Intervention: Nasal
Description: Nasal brushing by subject at J0

Intervention type: OTHER
Group type: OTHER
Intervention: Nasal
Description: Nasal brushing by subject at J0
Study: NCT06013215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cochlear implant (Oticon) stimulation parameter optimization
Description: The pulse amplitude and/or the pulse phase duration will be optimize to improve the intensity resolution of the cochlear implant which may benefit speech perception
Study: NCT05661188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus Tiraglolumab
Description: All patients receive atezolizumab (1200mg) plus tiragolumab (600 mg) for 2 cycles (Q3W) in concomitance with the 6 weeks of standard scheduled chemoradiotherapy (cisplatin: 60 mg/m² on days 1 and 29; 5-FU: 1000 mg/m² per day on days 1-4 and 29-32; radiotherapy: 1.8 Gy per day / total dose 54 Gy). After the concomitant phase, patients receive atezolizumab and tiragolumab for 6 additional cycles (consolidation phase).
Study: NCT06022289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib will be treated according to the treatment plan of 2 weeks of administration/1 week of discontinuation, with oral administration of 1 capsule, 13.5mg, QD, and a cycle of 21 days. Meanwhile, the molecular testing results of the patient are analyzed and interpreted by the MTB team, and appropriate combination therapy(Pemigatinib+) strategies are proposed based on the patient's previous treatment history, physical condition, drug accessibility, and economic status.
Study: NCT06218927

Intervention type: OTHER
Intervention: QoL monitoring
Description: QoL questionnaire
Study: NCT05507801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Milkshake
Description: A milkshake with high protein level; including whey protein, fat free strawberry yogurt and whole milk - 337 kcal, 27 g carbohydrate, 57 g protein, 16 g fat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Milkshake
Description: A milkshake with high protein level; including whey protein, fat free strawberry yogurt and whole milk - 337 kcal, 27 g carbohydrate, 57 g protein, 16 g fat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Milkshake
Description: A milkshake with normal protein level; including nesquik (strawberry), fat free strawberry yogurt, whole milk, double cream, whey protein and sweetener - 331 kcal, 64 g carbohydrate, 17 g protein, 19 g fat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Milkshake
Description: A milkshake with normal protein level; including nesquik (strawberry), fat free strawberry yogurt, whole milk, double cream, whey protein and sweetener - 331 kcal, 64 g carbohydrate, 17 g protein, 19 g fat.
Study: NCT05863962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking and Stretching
Description: Stretching exercise will be given for 6 weeks (3 sessions per week). 15 minutes of moderate walking with stretching exercises 5 times a week with Warm up and Cool down. Videos will be provided to participants to follow at home. Participants will be provided forms for home to fill after every session completed and frequency of each exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walking and Jacobsons relaxation technique
Description: Jacobson's Relaxation Technique will be given for 6 weeks. 15 minutes of moderate walking with Jacobson's Relaxation Technique. Videos will be provided to participants to follow at home. Participants will be provided forms for home to fill after every session completed. Participants will also bring their Pedometer
Study: NCT06013813

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial Artery approach on percutaneous coronary intervention (PCI)
Description: * Randomized patients with a right patent radial artery.~* The outcomes of the distal radial approach will be compared with those of the conventional radial approach.~* Technique and devices (introducer and compression devices) are the same in both approaches.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radial Artery approach on percutaneous coronary intervention (PCI)
Description: * Randomized patients with a right patent radial artery.~* The outcomes of the distal radial approach will be compared with those of the conventional radial approach.~* Technique and devices (introducer and compression devices) are the same in both approaches.
Study: NCT05658757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular sweetened commercial foods
Description: This is your usual habits period. Consume the chosen, sweetened commercial products of your choice in the breakfast cereal/cereal-granola bar category (at least 1 daily serving) and sweetened baked goods/candy/desserts (at least 1 daily serving).~* If you eat peanuts or nuts, and willingly consume chocolate covered peanuts or nuts, eat the regular sweetened chocolate covered nuts/peanuts at least 3 days a week (1 serving/day), or as frequently as your usual habits if more often.~* If you consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume these regular sweetened beverages as you usually do.
Study: NCT05018351

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Care
Description: Participants receive integrated physical and mental health care from their usual provider.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Navigation
Description: Peer navigators will meet individually and face-to-face with participants to address their health and weight goals (i.e. working on health-related goals, attending health care appointments. and facilitating follow-up activities related to healthcare appointments).
Study: NCT05658757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allulose sweetened commercial foods
Description: This period emphasizes minimizing added sugar, aligning intake levels with recommendations from the AHA and Dietary guidelines by consuming allulose sweetened products.~Participants will eat at least 1 daily serving of the chosen, provided allulose sweetened breakfast/cereal-granola bar, and at least 1 daily serving of allulose sweetened baked goods/candy/desserts in place of the usual sweetened products from these food categories.~* If they eat peanuts or nuts, and willingly consume chocolate covered peanuts or nuts, eat allulose sweetened chocolate covered nuts/peanuts at least 3 days a week (1 serving/day), or as frequently as usual habits if more often.~* If they consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume allulose sweetened beverages in place of their artificial or regular sweetened beverages (provided commercial and/or syrups), and sweeten coffee or tea with the provided allulose sweetener. Do this according to usual habits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole and minimally processed and sweetened foods
Description: Consume at least 1 daily serving of the chosen, minimal to no sweetened breakfast product in place of your usual sweetened breakfast cereal/cereal-granola bar and consume a whole piece of fruit (or serving of fruit) in place of a sweetened baked goods/candy/desserts (at least 1 daily serving).~* If you eat peanuts or nuts, consume plain or dry-roasted (no to low sodium) nuts/peanuts at least 3 days a week (1 serving), or as frequently as your usual habits if more often~* If you consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume unsweetened coffee or tea and consume plain water in place of the sweetened beverages at the same frequency/amount that you usually do.~This period emphasizes incorporating minimally processed (e.g., intact whole grains) foods with minimal to no added sugar, aligning added sugar intake levels with recommendations from the American Heart Association and Dietary guidelines.
Study: NCT05943730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seismofit
Description: The Seismofit device uses seismocardiography to estimate peak oxygen consumption from a resting measurement. This study will assess its validity against the gold standard measure of peak oxygen consumption, cardiopulmonary exercise test, conducted as part of standard care.
Study: NCT05548478

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transepithelial PRK/MMC
Description: transepithelial photorefractive keratectomy (PRK) and mitomycin C addition

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol-Assisted PRK/MMC
Description: photorefractive keratectomy (PRK) assisted by alchol and mitomycin C addition
Study: NCT06351202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Description: An abdominal massage for premature babies lasts 10 minutes. Our abdominal massage techniques is described in our protocole and will be adapted according to the term of the child.
Study: NCT04205435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: β-globin restored autologous HSC
Description: gene edited autologous hematopoietic stem cells with β-globin restoration
Study: NCT05071131

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: 1 sachet à 15 grams daily for 7 days, followed by 2 sachets à 15 grams daily for 28 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sachet à 15 grams daily for 7 days, followed by 2 sachets à 15 grams daily for 28 days
Study: NCT06272175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open Kinetic Chain Activity
Description: PNF Flexion-Abduction-External Rotation and Flexion-Adduction-External Rotation patterns will be actively performed on the hemiplegic upper extremity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed Kinetic Chain Activity
Description: Weight-bearing on the hemiplegic hand with extended elbow in standing position
Study: NCT05223153

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence tomography angiography
Description: Measurement retinal vessel density in the superficial and deep capillary plexuses using OCTA in children with anisometropic amblyopia

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence tomography angiography
Description: Measurement retinal vessel density in the superficial and deep capillary plexuses using OCTA in children with anisometropic amblyopia
Study: NCT04718844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124
Description: SLN124 for subcutaneous (s.c.) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124
Description: SLN124 for subcutaneous (s.c.) injection
Study: NCT04886973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids.
Description: Intravenous administration of 8% crystalline L-amino acids with high concentrations of branched chain amino acids.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of an 8% crystalline L-amino acid solution with high concentrations of branched chain amino acids.
Description: Intravenous administration of 8% crystalline L-amino acids with high concentrations of branched chain amino acids.
Study: NCT04718844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124
Description: SLN124 for subcutaneous (s.c.) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124
Description: SLN124 for subcutaneous (s.c.) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124
Description: SLN124 for subcutaneous (s.c.) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124
Description: SLN124 for subcutaneous (s.c.) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124
Description: SLN124 for subcutaneous (s.c.) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124
Description: SLN124 for subcutaneous (s.c.) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124
Description: SLN124 for subcutaneous (s.c.) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124
Description: SLN124 for subcutaneous (s.c.) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124
Description: SLN124 for subcutaneous (s.c.) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124
Description: SLN124 for subcutaneous (s.c.) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124
Description: SLN124 for subcutaneous (s.c.) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN124
Description: SLN124 for subcutaneous (s.c.) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride for s.c. injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride for s.c. injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride for s.c. injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride for s.c. injection
Study: NCT05790161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 2mg/kg, once before night 6 and once before the scan (either on week 1 or 2, alternating with placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 2mg/kg, once before night 6 and once before the scan (either on week 1 or 2, alternating with placebo)
Study: NCT06074042

Intervention type: OTHER
Intervention: previous pulmonary tuberculosis
Description: Previous pulmonary tuberculosis is comprehensively evaluated by the self-reported medical history, T-SPOT.TB test and radiological findings.
Study: NCT04963842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of bio-plastic food packaging material and avoidance of plastic food packaging material
Description: The bio-plastic food packaging material will be used by the study participants for 5 days and no plastic packaged food will be consumed.
Study: NCT05607264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinsiotaping
Description: Patients received the kinesiotaping over supraspinatus muscle and deltoid muscle, tape will be removed every three days and subjects will return back to the clinic to reapplication of tape again. Patients received the same therapeutic treatment 3 times/ week for four weeks. KT is air permeable and water resistant, allowing it to stay in place for three to five days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion-controlled VR games
Description: Virtual Rehab utilizes the unique characteristics of Microsoft Kinects motion technology to track and capture the movements of the patients so that patients become immersed in a 3D environment where they interact with the game. Subjects will include in a supervised virtual reality exergaming program for shoulder movements for 4 weeks, 3 days per week and 10 minutes for session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: patients received conventional treatment for chronic shoulder impingement syndrome only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: patients received conventional treatment for chronic shoulder impingement syndrome only.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: patients received conventional treatment for chronic shoulder impingement syndrome only.
Study: NCT05817747

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dialogue support tool
Description: The dialogue support tool will be used as a support for the participant and surgeon to decide on which treatment arm is optimal for the participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialogue support tool
Description: The dialogue support tool will be used as a support for the participant and surgeon to decide on which treatment arm is optimal for the participant.
Study: NCT06351683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MitoQ (mitoquinol mesylate)
Description: MitoQ is an antioxidant molecule designed to target cell stress

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control capsules that contain all inactive ingredients found in the study drug capsules (i.e., placebo capsules do not contain mitoquinol mesylate)
Study: NCT05596266

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD5 CAR-T
Description: CD5 CAR-T will be administered by I.V. infusion.
Study: NCT05020561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group life-coaching
Description: Group coaching sessions will be focusing on providing material and tools that guide the participants in the transition from cancer treatment to survivorship. All activities of the group session will be following the After Cancer Passport document.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group life-coaching
Description: Group coaching sessions will be focusing on providing material and tools that guide the participants in the transition from cancer treatment to survivorship. All activities of the group session will be following the After Cancer Passport document.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual life-coaching
Description: In the individual coaching sessions, the life-coach will provide guidances that help the participants to put tools into actions. All activities are outlined in the After Cancer Passport. Participants will use their Passport for each individual coaching session to outline their objectives and indicators of success. The life coach will also assign activities, such as self-reflection, for the participants to complete between each session.
Study: NCT03872505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: IV administration of 5 treatments;every 2 weeks for 2 treatments and then every 4 weeks for 3 treatments

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: IV administration of 5 treatments;every 2 weeks for 2 treatments and then every 4 weeks for 3 treatments

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: The second dose of durvalumab will be given in conjunction with an RT boost, consisting of 8 Gy in 3 fractions for a total of 24 Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV administration weekly for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV administration weekly for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV administration every week for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV administration every week for 12 weeks
Study: NCT05082779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS0159
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS0159
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS0159
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS0159
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS0159
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS0159
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS0159
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS0159
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS0159
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS0159
Description: Tablets administered orally
Study: NCT04892368

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based supervised exercise program
Description: Combination of aerobic and strength training exercises, in addition to home exercise instructions issued during preoperative physiotherapy education.
Study: NCT05639244

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Time restricted eating (TRE)
Description: Participants have to consume their regular food intake during a 6 hour period per day for 2 weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Time restricted eating (TRE)
Description: Participants have to consume their regular food intake during a 6 hour period per day for 2 weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Regular diet
Description: Participants have to consume their regular diet within an unrestricted time period for 2 weeks

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Regular diet
Description: Participants have to consume their regular diet within an unrestricted time period for 2 weeks
Study: NCT06561022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluzoparib
Description: Fluzoparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant
Study: NCT06102330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HomeVENT decision support tool
Description: Web-based decision support tool that describes diverse family experiences with making decisions about pediatric chronic home ventilation